Study Design of the EDGEFIRM Trial: TEER Versus GDMT in Atrial Functional Mitral Regurgitation and HFpEF.
New randomized trial will test catheter-based heart repair for a specific heart failure type lacking prior intervention evidence.
The EDGEFIRM trial protocol describes a randomized controlled trial comparing transcatheter edge-to-edge repair (TEER/MitraClip) versus guideline-directed medical therapy in patients with atrial functional mitral regurgitation and HFpEF, a specific HF subtype with limited interventional evidence. Announcement of this trial design is relevant for tracking emerging cardiovascular intervention evidence.
What the study was
- Study design
- Randomized controlled trial design paper
- Population
- Patients with atrial functional mitral regurgitation and HFpEF
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- ESC heart failure
Why it surfaced
HFpEF with atrial functional MR is a large under-addressed clinical population. First dedicated RCT (EDGEFIRM) comparing TEER vs medical therapy represents a significant trial design to track.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.